Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Laeyendecker, Oliver ^a,b   Kulich, Michal ^c   Donnell, Deborah ^d   Komárek, Arnošt ^c   Omelka, Marek ^c   Mullis, Caroline E ^b   Szekeres, Greg ^e   Piwowar Manning, Estelle ^b   Fiamma, Agnes ^e   Gray, Ronald H ^f,g   Lutalo, Tom ^g   Morrison, Charles S ^h   Salata, Robert A ^i,j   Chipato, Tsungai ^k   Celum, Connie ^l   Kahle, Erin M ^l   Taha, Taha E ^f   Kumwenda, Newton I ^f   Karim, Quarraisha Abdool ^m,n   Naranbhai, Vivek ⁿ   Lingappa, Jairam R ^l   Sweat, Michael D ^o   Coates, Thomas ^e   Eshleman, Susan H ^b   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^h FAMILY HEALTH INTERNATIONAL   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^l UNIVERSITY OF WASHINGTON   (United States)

^m University of Washington ^*  (United States)

ⁿ UNIVERSITY OF KWAZULU NATAL   (South Africa)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ALGORITHMS; CROSS-SECTIONAL STUDIES; EPIDEMICS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893582417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078818     Document Type: Article

References (36)

1. Brookmeyer R (2010) Measuring the HIV/AIDS epidemic: approaches and challenges. Epidemiol Rev 32: 26-37.
2. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, et al. (2010) Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 24: 2763-2771.
3. Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, et al. (2013) Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis 13: 65-76.
4. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, et al. (2011) HIV prevention transformed: the new prevention research agenda. Lancet 378: 269-278.
5. Sweat M, Morin S, Celentano D, Mulawa M, Singh B, et al. (2011) Communitybased intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis 11: 525-532.
6. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623-2628. (Pubitemid 38747513)
7. UNAIDS Reference Group on Estimates MaP (2006) Statement on the use of the BED assay for estimation of HIV-1 incidence or epidemic monitoriing. Weekly Epidemiological Record 81: 33-40.
8. Mastro TD (2012) Determining HIV Incidence in Populations: Moving in the Right Direction. J Infect Dis.
9. Laeyendecker O, Wang L, Hughes J, Cummings V, Piwowar-Manning E, et al. (2013) Use of a multi-assay algorithm for cross-sectional HIV incidence estimation in HPTN 061 (the Brothers Study). 20th Conf on Retroviruses and Opportunistic Infections. Atlanta, GA. pp. Abstract# 1053.
10. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, et al. (2013) HIV Incidence determination in the United States: A multi-assay approach. Journal of Infectious Diseases 207: 232-239.
11. Eshleman S, Hughes J, Laeyendecker O, Wang J, Brookmeyer R, et al. (2013) Comparison of three methods for assessing HIV incidence in a cohort study of women in the United States: HPTN 064. Journal of Infectious Diseases 207: 223-231.
12. Piwowar-Manning E, Fiamma A, Laeyendecker O, Kulich M, Donnell D, et al. (2011) HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043). BMC Infect Dis 11: 251.
13. Brookmeyer R (2009) Should biomarker estimates of HIV incidence be adjusted? AIDS 23: 485-491.
14. Brookmeyer R (2010) On the statistical accuracy of biomarker assays for HIV incidence. J Acquir Immune Defic Syndr 54: 406-414.
15. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, et al. (2008) The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr 48: 211-215.
16. Laeyendecker O, Brookmeyer R, Mullis C, Donnell D, Lingappa J, et al. (2012) Specificity of four laboratory approaches for cross-sectional HIV incidence determination: Analysis of samples from adults with known non-recent HIV infection from five African countries. AIDS Res Hum Retroviruses 28: 1177-83.
17. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, et al. (2003) Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses 19: 481-486. (Pubitemid 36793768)
18. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, et al. (2011) Determination of Mean Recency Period for Estimation of HIV Type 1 Incidence with the BED-Capture EIA in Persons Infected with Diverse Subtypes. AIDS Res Hum Retroviruses 27: 265-273.
19. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, et al. (2010) Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 53: 496-499.
20. Hayashida T, Gatanaga H, Tanuma J, Oka S (2008) Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 24: 495-498. (Pubitemid 351457743)
21. Hallett TB, Ghys P, Barnighausen T, Yan P, Garnett GP (2009) Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One 4: e5720.
22. Kulich M, Laeyendecker O, Eshleman SH, Komarek A, Omelka M, et al. (2013) Evaluation of multi-assay algorithms for cross-sectional HIV incidence estimation. Submitted.
23. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
24. Morrison CS, Chen PL, Nankya I, Rinaldi A, Van Der Pol B, et al. (2011) Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 57: 157-164.
25. Campbell MS, Mullins JI, Hughes JP, Celum C, Wong KG, et al. (2011) Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One 6: e16986.
26. Arroyo MA, Sateren WB, Serwadda D, Gray RH, Wawer MJ, et al. (2006) Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr 43: 440-445. (Pubitemid 44737102)
27. Conroy SA, Laeyendecker O, Redd AD, Collinson-Streng A, Kong X, et al. (2010) Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002. AIDS Res Hum Retroviruses 26: 1087-1091.
28. Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, et al. (2012) CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis 206: 35-40.
29. Masciotra S, Dobbs T, Candal D, Hanson D, Delaney K, et al. (2010) Antibody avidity-based assay for identifying recent HIV-1 infections based on genetic systems TM 1/2 plus O EIA. 17th Conference on Retroviruses and Opportunistic Infections, abstract 937. San Francisco, CA; Feb 16-19.
30. Mullis CE, Munshaw S, Grabowski MK, Serwadda D, R B, et al. (2012) Differential misclassification of HIV-1 cross-sectional incidence assays by subtype in Rakai, Uganda. 18th Conference on Retroviruses and Opportunistic Infections, abstract 541. Seattle, WA.
31. Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, et al. (Submitted 2013) Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH Project Accept (HIV Prevention Trials Network 043).
32. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
33. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371: 2109-2119. (Pubitemid 351902179)
34. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427-439.
35. Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, et al. (2008) Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 359: 119-129. (Pubitemid 351962035)
36. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, et al. (1999) Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 353: 525-535. (Pubitemid 29078422)